Medical Device Daily Features Cardima's Technology to Treat Atrial Fibrillation.

Business Editors & Health/Medical Writers

FREMONT, Calif.--(BUSINESS WIRE)--Dec. 19, 2002

Cardima, Inc. (Nasdaq:CRDM) today announced that its REVELATION(R) microcatheter technology to treat atrial fibrillation (AF) was featured as a lead article in the December 11, 2002 issue of Medical Device Daily (MDD), written by Holland Johnson, MDD Senior Staff Writer. The full text of the article is available on the Company's Web site at www.cardima.com.

The article, entitled "Cardima is Finding its Niche with Atrial Fibrillation Devices," highlights the Company's technology, especially the REVELATION(R) family of microcatheters that are designed to treat AF in a minimally invasive procedure. The technology is used to ablate AF by creating long, thin, linear lesions in the atrium of the heart, replicating the curative lines of scar created by the surgical maze procedure. The surgical maze is the only procedure to date known to provide a long-term cure; however, it is only done in conjunction with other open-heart surgical procedures. The article also discusses the FDA's acceptance of the Company's premarket approval (PMA) application and grant of expedited review for the REVELATION Tx.

The article includes comments by Dr. Hugh Calkins, professor of medicine and Director of Electrophysiology Services at Johns Hopkins University in Baltimore, who participated in the right-sided linear ablation trial for the Revelation Tx. According to Dr. Calkins, "Three months after ablation 38% of patients had no AF and six months after ablation 47% had no AF."

Additionally, Dr. Calkins noted that the study group had significant episode reduction in symptomatic AF. The study group recorded an average of 10 AF episodes per month prior to ablation, an average of 3.7 AF episodes per month three months after ablation, and an average of 1.9 AF episodes per month six months after ablation.

Dr. Calkins commented, "This is the first prospective, multi-center clinical trial for catheter ablation of atrial fibrillation that has reached the finish line. I think that's the enormous hurdle that has been crossed. There were about 10 other companies that started the race, but all the rest packed it in. Cardima had the fortitude to stick with it and present us with results."

Dr. Calkins further noted that catheter ablation resulted in a significant improvement in quality of life. "I think catheter ablation will be routinely performed to cure afib -- that's clearly where we're moving," he commented.

Cardima, Inc. developed the REVELATION(R) Tx linear ablation microcatheter system as a minimally invasive, single-use product that may have the potential for curing AF. The REVELATION(R) Tx linear ablation microcatheter system is believed by the Company to be the first device to treat AF that has completed a multi-center clinical trial and has had a pre-market approval (PMA) application submitted to the FDA. Cardima submitted the PMA on September 20, 2002 and was granted expedited review status by the FDA on November 5, 2002. Clinical trial data from the REVELATION(R) Tx microcatheter demonstrated safety and promising efficacy. Cardima's mission is to get better devices to treat AF in the hands of the medical community.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include the Company's ability to raise additional capital, whether the Company's premarket approval application will be approved by the U.S. FDA, and whether the Company will be able to conduct successful clinical trials, obtain regulatory approvals and gain acceptance from the marketplace for its products. Additional risks are set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2001, filed with the Securities and Exchange Commission on April 1, 2002, and the Company's Quarterly Reports on Form 10-Q for the Quarters ended March 31, June 30, and September 30, 2002. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.